{"entity":{"id":"inobrodib","kind":"drug","name":"Inobrodib","aka":["CCS1477"],"tldr":"Inobrodib is an experimental pill from CellCentric, in phase 3 trials for relapsed or refractory multiple myeloma.","summary":"Inobrodib (CCS1477) is a small molecule, oral from CellCentric. Blocks the bromodomain of p300 (EP300) and CBP (CREBBP), two proteins that switch on genes, lowering the activity of cancer genes including MYC and IRF4. A phase 3 study with pomalidomide and dexamethasone (NCT07772024, started August 2026) and a phase 2 study (NCT07096778) are recruiting in relapsed or refractory myeloma; earlier studies covered blood cancers (NCT04068597) and advanced solid tumours (NCT03568656). The company says the FDA granted Fast Track and orphan drug designations in relapsed or refractory myeloma.","status":"phase-3","asOf":"2026-11-04","links":[{"label":"CellCentric clinical trials","url":"https://www.cellcentric.com/clinical-trials/"},{"label":"CellCentric Series D release, May 2026","url":"https://www.cellcentric.com/press-release/cellcentric-announces-oversubscribed-220-million-series-d-financing-to-advance-pivotal-trials-of-inobrodib-in-multiple-myeloma/"},{"label":"ClinicalTrials.gov NCT04068597","url":"https://clinicaltrials.gov/study/NCT04068597"},{"label":"ClinicalTrials.gov NCT07772024","url":"https://clinicaltrials.gov/study/NCT07772024"},{"label":"ClinicalTrials.gov NCT07096778","url":"https://clinicaltrials.gov/study/NCT07096778"},{"label":"ClinicalTrials.gov NCT03568656","url":"https://clinicaltrials.gov/study/NCT03568656"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":["ep300","crebbp"],"drugs":[],"companies":["cellcentric"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04068597","nct07772024","nct07096778","nct03568656"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"CCS1477","modality":"Small molecule, oral","mechanism":"Blocks the bromodomain of p300 (EP300) and CBP (CREBBP), two proteins that switch on genes, lowering the activity of cancer genes including MYC and IRF4.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/inobrodib/","neighbours":{"cancer":[{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"target":[{"id":"crebbp","kind":"target","name":"CREBBP","route":"/targets/crebbp/"},{"id":"ep300","kind":"target","name":"EP300","route":"/targets/ep300/"}],"company":[{"id":"cellcentric","kind":"company","name":"CellCentric","route":"/companies/cellcentric/"}],"trial":[{"id":"nct07096778","kind":"trial","name":"Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07096778/"},{"id":"nct07772024","kind":"trial","name":"Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07772024/"},{"id":"nct04068597","kind":"trial","name":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","route":"/trials/nct04068597/"},{"id":"nct03568656","kind":"trial","name":"Study to Evaluate CCS1477 in Advanced Tumours","route":"/trials/nct03568656/"}]}}